1. Home
  2. BNR vs NEPH Comparison

BNR vs NEPH Comparison

Compare BNR & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNR
  • NEPH
  • Stock Information
  • Founded
  • BNR 2014
  • NEPH 1997
  • Country
  • BNR China
  • NEPH United States
  • Employees
  • BNR N/A
  • NEPH 31
  • Industry
  • BNR Medical Specialities
  • NEPH Medical/Dental Instruments
  • Sector
  • BNR Health Care
  • NEPH Health Care
  • Exchange
  • BNR Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • BNR 38.3M
  • NEPH 45.3M
  • IPO Year
  • BNR 2020
  • NEPH 2004
  • Fundamental
  • Price
  • BNR $8.37
  • NEPH $4.13
  • Analyst Decision
  • BNR
  • NEPH Strong Buy
  • Analyst Count
  • BNR 0
  • NEPH 2
  • Target Price
  • BNR N/A
  • NEPH $5.50
  • AVG Volume (30 Days)
  • BNR 38.7K
  • NEPH 57.3K
  • Earning Date
  • BNR 09-08-2025
  • NEPH 11-06-2025
  • Dividend Yield
  • BNR N/A
  • NEPH N/A
  • EPS Growth
  • BNR N/A
  • NEPH N/A
  • EPS
  • BNR N/A
  • NEPH 0.12
  • Revenue
  • BNR $74,862,782.00
  • NEPH $16,684,000.00
  • Revenue This Year
  • BNR $136.32
  • NEPH $24.38
  • Revenue Next Year
  • BNR N/A
  • NEPH $10.16
  • P/E Ratio
  • BNR N/A
  • NEPH $36.25
  • Revenue Growth
  • BNR 5.20
  • NEPH 21.16
  • 52 Week Low
  • BNR $2.18
  • NEPH $1.36
  • 52 Week High
  • BNR $11.12
  • NEPH $5.00
  • Technical
  • Relative Strength Index (RSI)
  • BNR 51.90
  • NEPH 51.37
  • Support Level
  • BNR $8.02
  • NEPH $3.62
  • Resistance Level
  • BNR $9.55
  • NEPH $4.94
  • Average True Range (ATR)
  • BNR 0.67
  • NEPH 0.41
  • MACD
  • BNR -0.15
  • NEPH -0.00
  • Stochastic Oscillator
  • BNR 30.29
  • NEPH 38.64

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: